Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.

Latest Resources

• Crafting Crisis
• Community Healthlink In Massachusetts Prepares Program Transitions Ahead Of Closure
• One-Third Of Outpatient Behavioral Health Facilities Offer Programs Tailored For Older Adults
• Youth Cannabis Use Associated With Slower Cognitive Development & Reduced Gains In Memory, Attention & Processing Speed
• Clark County Opens Crisis Stabilization Center In Southern Nevada
• SAMHSA Prohibits Use Of Grant Funding For Fentanyl Test Strips & Overdose Hotlines In Updated Guidance
• Medicaid Member Use Of MOUD Increases to 69% 
• Updated Funding Guidance For Grantees On Supplies & Services
• Behavioral Health Parity Gap Persists In 43 States
• Model Standards for Crisis Care Workers
• Findhelp & MiResource Partner To Improve Behavioral & Mental Health Care Access With Directory Accuracy
• Presidential Executive Order Focuses On Psychedelic Medication; FDA Announces Shortened Review Process
• Monthly Injectable Buprenorphine May Reduce Staffing Time & Costs For OUD Treatment In Correctional Settings, Simulation Finds
• Rural Maine School District To Launch Recovery High School Model For Students With Substance Use Disorders
• Alameda County, California Superior Court Seeks A Continuum Of Drug Court Services Through Rolling Procurement

See All

GLP-1 Medications Linked To 15%–20% Lower Risk Of Substance Use Disorders In Veterans With Type 2 Diabetes

Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read

• Federal 2027 Budget Proposal Would Eliminate SAMHSA As Stand-Alone Agency & Reduce Behavioral Health Funding By 8%
• Federal Agencies Decline To Defend 2024 Mental Health Parity Rule & Prepare For New Proposal In 2026
• Public Comment Period Open For The Solano County, California Behavioral Health Services Act 2026-2029 Integrated Plan
• Wyoming Rebids Jail & Community Corrections IOP Addiction Treatment Contracts With July 2026 Start
• Qualifacts Acquires MethodOne To Fully Integrate Medication-Assisted Treatment Into Its EHR Platforms For Substance Use Disorder Provider Organizations

To sign-up for bi-weekly Mental Health alerts, you must be signed in to your account.